Let’s start up with the current stock price of Vascular Biogenics Ltd. (VBLT), which is $2.25 to be very precise. The Stock rose vividly during the last session to $2.70 after opening rate of $2.57 while the lowest price it went was recorded $2.5561 before closing at $2.67.
Recently in News on June 15, 2021, VBL Therapeutics Provides Update on OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer. VBL Therapeutics (Nasdaq: VBLT) today provided an update on its ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111), for the treatment of platinum-resistant ovarian cancer. You can read further details here
Vascular Biogenics Ltd. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $3.17 on 02/23/21, with the lowest value was $1.65 for the same time period, recorded on 03/05/21.
Vascular Biogenics Ltd. (VBLT) full year performance was 118.85%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Vascular Biogenics Ltd. shares are logging -29.02% during the 52-week period from high price, and 122.29% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.01 and $3.17.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1695227 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Vascular Biogenics Ltd. (VBLT) recorded performance in the market was 41.27%, having the revenues showcasing 24.77% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 145.35M, as it employees total of 38 workers.
The Analysts eye on Vascular Biogenics Ltd. (VBLT)
During the last month, 5 analysts gave the Vascular Biogenics Ltd. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 2.16, with a change in the price was noted -0.27. In a similar fashion, Vascular Biogenics Ltd. posted a movement of -10.51% for the period of last 100 days, recording 971,118 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for VBLT is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical rundown of Vascular Biogenics Ltd. (VBLT)
Raw Stochastic average of Vascular Biogenics Ltd. in the period of last 50 days is set at 45.32%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 22.77%. In the last 20 days, the company’s Stochastic %K was 49.44% and its Stochastic %D was recorded 56.52%.
Considering, the past performance of Vascular Biogenics Ltd., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 41.27%. Additionally, trading for the stock in the period of the last six months notably improved by 72.26%, alongside a boost of 118.85% for the period of the last 12 months. The shares increased approximately by 1.91% in the 7-day charts and went down by 37.63% in the period of the last 30 days. Common stock shares were driven by 24.77% during last recorded quarter.